In 17 (33.3%) additional patients, the disease stabilized for at least 3 months, for a hepatic disease control rate of 82.4%. After median follow-up of 367 days, median overall progression free (PFS) and hepatic progression free survival (hPFS) was 8.1 and 9.1 months, respectively and median overall survival was 15.3 months. There were no treatment related fatalities. Non-hematologic grade 3-4 events were seen in 19 (37.5%) patients and were mainly coagulopathic (N = 8) and cardiovascular (N = 9).
By utilizing advanced endovascular techniques, Percutaneous
Hepatic Perfusion (PHP) significantly improves on this concept. A Phase I trial 20 demonstrated the feasibility of this approach and a
Phase III trial 21 revealed a significantly improved primary end point of hepatic progression free survival (hPFS) as well as a significantly improved overall progression free survival (PFS) against best alternative care. Median overall survival (OS) was not significantly different between the groups but a high crossover rate (58%) made the effect on survival difficult to interpret.
In 2010, PHP became available for use at our institutions while a second phase III trial was planned. We present our multicentre experience with M-PHP and compare our results with the original outcomes for UM patients in the Phase III study to investigate the safety and feasibility of delivering this technique outside a clinical trial setting.
METHODS

Patient eligibility
All patients with histologically confirmed UM who underwent M-PHP The catheter is then connected to an extracorporeal circulation system consisting of a centrifugal pump and two drug filtration activated carbon filters ( Figure 1 ). Blood is aspirated through catheter fenestrations in a segment between the two balloons, actively pumped through the filtration system and returned through the sheath in the IJV. Once correct positioning of the two balloons is confirmed, the filtration of blood by the two cartridges is started in a stepwise fashion. A centrifugal pump is used to achieve appropriate flow rates. The hemofiltration filters are brought online and once the cartridges are completely filled with blood, the bypass line is closed. When the hemofiltration circuit is running adequately and the patient is hemodynamically stable intra-arterial infusion of melphalan is started. disease progression was felt to be attributable to differential perfusion of liver parenchyma due to anatomic constraints, subsequent attempts with M-PHP would be made to preferentially target these areas.
Response assessment
Either a dedicated liver MRI or a triple phase liver CT was performed to assess tumor response following the guidelines set forth in RECIST 1.1.
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Data capture and analysis
Data was collected retrospectively from the electronic medical record.
GraphPad Prism Version 6.01 was used for survival curve graphing and analysis using the Kaplan-Meier method; log-rank test was used to compare curves and determine the P value. SPSS version 23.0.0 was used for Cox regression analysis.
RESULTS
Patient characteristics
Fifty-one patients with metastatic UM commenced M-PHP between
December of 2008 and October of 2016 at our two centres. All patients had pathologically confirmed metastatic UM to the liver and radiologically confirmed hepatic progression; 8/51 patients (15.7%) also had limited extrahepatic disease. Baseline patient characteristics are presented in Table 1 .
All patients underwent at least 1 M-PHP. At data collection cut-off time, two patients were lost to follow-up and 17 patients were still alive; a median of two cycles of M-PHP had been administered per patient, 134 M-PHPs in total. Of these, seven patients were continuing on treatment, and 15 patients had completed the planned full course. Twenty-nine patients discontinued early; nine due to treatment related toxicity, 17 due to disease progression, and three due to patient preference.
Response analysis
Radiological assessments took place as clinically indicated, typically 6-8 weeks after each treatment. Figure 2 illustrates by way of a waterfall plot the magnitude of observed responses.
In 17/51 (33.3%) patients, the best hepatic response was stable disease (SD) for a minimum of three months; in 11 this was 
Survival analysis
After a median follow-up of 12.2 months, at the time of data cut off, median OS was 15.3 months. Seventeen patients were still alive, five on-treatment, 32 had passed away and two were lost to follow-up.
One year OS rate is 64.6% ( Figure 3A 
Safety analysis
M-PHP was well tolerated in this study population with frequency and adverse events types commensurate with those reported in the original Phase III study 21 (Table 3 ). There were no treatment related fatalities. Nineteen patients (37.5%) experienced grade 3-4 nonhematologic treatment related toxicity. Cardiovascular toxicity was primarily observed peri-procedurally-three cases of ventricular tachycardia and one case of supraventricular tachycardia were seen.
There were five cases of post-operative troponin elevation, one with associated ECG changes suggestive of non-ST elevation myocardial infarction and one associated with pulmonary oedema. In addition there were two episodes of pulmonary oedema without documented associated myocardial ischaemia.
Bleeding events were common peri-operatively and seen in 19.6% of patients, but most were minor. There was 1 case each of DIC requiring prolonged clotting factor support, intra-abdominal bleeding, and intracerebral haemorrhage-not tumor related-all resolved with no long term sequelae. Table 3 .
DISCUSSION
This retrospective analysis of UM patients treated with M-PHP at two institutions demonstrates that M-PHP can be administered safely and effectively in high volume treatment centres in appropriately selected patients. Additionally, toxicity rates are comparable to those reported in the phase III trial 21 : cardiovascular toxicity was seen in nine patients (17.6%) versus 12 (17%) in the phase III trial; severe neutropenia was seen in 16 (31.4%) patients as opposed to 60 (85.7%), and there were only four cases (7.8%) of febrile neutropenia as opposed to 12 (17.1%). Importantly, while the trial PHP related mortality was 6% (4/70 patients), in our series there were no treatment related deaths.
The explanation for improved safety outcomes is likely multifactorial. Our patients were treated in high volume centres-carrying out more than six procedures per year-by experienced teams. Patient selection criteria were strict: patients with known extrahepatic disease were only offered treatment if it was amenable to resection or ablation.
Physiological fitness was formally assessed by experienced intensivists, only one patient treated had a history of cardio-or cerebrovascular disease-a transient ischaemic attack 5 years prior to the first treatment-and none had a known history of bleeding or prothrombotic tendencies All patients had an ECOG performance status of 1 or better. Patients with heavy disease burden had to have preserved hepatic function.
A second generation filter was used that might have contributed to increased melphalan extraction, reducing late bone marrow suppression. Finally, the median number of cycles of M-PHP received was lower than in the trial, largely due to logistical issues at one of the treatment centres-a median of two cycles at UHS versus 3 at Moffitt
Cancer Center and the phase III trial.
Despite the lower number of administered procedures per patient, hepatic responses were seen in a similar proportion of patients: 49% in the current study versus 36% in the previous phase III trial.
Additionally, the current study demonstrated high hepatic disease control rates; median hPFS was at 9.1 months in the current report versus 8.2 months in the trial. Most importantly, OS rates were encouraging when compared with historical data-64.6% at 1 year in Finally, we need to consider that improved outcomes may simply be a "stage migration"-like effect due to selection of patients with earlier disease. Historically presentation was late and driven by chance findings of deranged liver function tests or symptoms relating to liver capsule pain or biliary tract obstruction. As more treatment modalities are becoming available, there has been increased recognition of the importance of early diagnosis and routine biannual liver imaging in high-risk patients is now considered standard practice. 23 The debate regarding the merit of regional therapy in melanoma and in particular of liver directed therapy in UM is longstanding. 24 It is unfortunate that the original phase III randomized control trial of M-PHP versus best alternative care allowed for both large scale 
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